Illumina's Q3 Revenues Jump 50 Percent on Strength of HiSeq | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Illumina reported after the close of the market Tuesday that its third-quarter revenues jumped 50 percent, easily beating analysts' consensus estimate.

The San Diego-based sequencing and array technologies firm reported total revenues of $237.3 million for the three-month period ended Oct. 3, compared to $158.4 million for the third quarter of 2009. Analysts had expected the firm to post revenues of $218.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.